https://www.selleckchem.com/pr....oducts/tiragolumab-a
, leading to potentially tighter binding than U with a target protein or nucleic acid and potential use for various biochemical and pharmacological applications.Tuberculosis (T remains a foremost poverty-related disease with a high rate of mortality despite global immunization with Bacille Calmette-Guérin (BCG). Several adjuvanted recombinant proteins are in clinical development for TB to protect against the disease in infants and adults. Nevertheless, simple mixing of adjuvants with antigens may not be optimal for enha
Like
Comment
Share
